A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see how safe Androderm® (the study drug) is at three
different doses in subjects with early hormone refractory prostate cancer. In addition,
information about hormonal levels and the effects of testosterone on quality of life
including sexual functioning and muscle strength will be collected.